Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$30.0 - $39.95 $45,000 - $59,925
-1,500 Reduced 68.18%
700 $27,000
Q2 2024

Aug 14, 2024

SELL
$28.81 - $33.01 $164,217 - $188,157
-5,700 Reduced 72.15%
2,200 $66,000
Q1 2024

May 15, 2024

SELL
$29.93 - $35.06 $442,964 - $518,888
-14,800 Reduced 65.2%
7,900 $265,000
Q4 2023

Feb 14, 2024

BUY
$19.2 - $33.78 $360,960 - $635,064
18,800 Added 482.05%
22,700 $733,000
Q3 2023

Nov 14, 2023

SELL
$31.89 - $39.03 $95,670 - $117,090
-3,000 Reduced 43.48%
3,900 $127,000
Q2 2023

Aug 14, 2023

SELL
$30.5 - $37.4 $518,500 - $635,800
-17,000 Reduced 71.13%
6,900 $242,000
Q1 2023

May 15, 2023

BUY
$30.8 - $53.92 $689,920 - $1.21 Million
22,400 Added 1493.33%
23,900 $780,000
Q4 2022

Feb 14, 2023

SELL
$45.4 - $60.91 $3.82 Million - $5.12 Million
-84,100 Reduced 98.25%
1,500 $82,000
Q3 2022

Nov 14, 2022

BUY
$42.06 - $55.45 $2.19 Million - $2.88 Million
52,000 Added 154.76%
85,600 $3.79 Million

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.07B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.